Relay Therapeutics, Inc. (RLAY)
RLAY Stock Price Chart
Explore Relay Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze RLAY price movements and trends.
RLAY Company Profile
Discover essential business fundamentals and corporate details for Relay Therapeutics, Inc. (RLAY) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
16 Jul 2020
Employees
259.00
Website
https://www.relaytx.comCEO
Sanjiv K. Patel MBBS
Description
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
RLAY Financial Timeline
Browse a chronological timeline of Relay Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 24 Feb 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is -$0.41, while revenue estimate is $160.00K.
Earnings released on 7 Aug 2025
EPS came in at -$0.41 surpassing the estimated -$0.49 by +16.33%, while revenue for the quarter reached $677.00K , beating expectations by +4.64K%.
Earnings released on 5 May 2025
EPS came in at -$0.46 surpassing the estimated -$0.50 by +8.00%, while revenue for the quarter reached $7.68M , beating expectations by +104.09%.
Earnings released on 26 Feb 2025
EPS came in at -$0.45 surpassing the estimated -$0.57 by +21.05%.
Earnings released on 6 Nov 2024
EPS came in at -$0.63 surpassing the estimated -$0.77 by +18.18%.
Earnings released on 6 Aug 2024
EPS came in at -$0.69 surpassing the estimated -$0.73 by +5.48%.
Earnings released on 2 May 2024
EPS came in at -$0.62 surpassing the estimated -$0.70 by +11.43%, while revenue for the quarter reached $10.01M , beating expectations by +33.26K%.
Earnings released on 22 Feb 2024
EPS came in at -$0.67 surpassing the estimated -$0.76 by +11.84%, while revenue for the quarter reached -$1.00K , missing expectations by -100.77%.
Earnings released on 2 Nov 2023
EPS came in at -$0.54 surpassing the estimated -$0.83 by +34.94%, while revenue for the quarter reached $25.20M , beating expectations by +6.71K%.
Earnings released on 8 Aug 2023
EPS came in at -$0.81 falling short of the estimated -$0.78 by -3.85%, while revenue for the quarter reached $119.00K , missing expectations by -84.13%.
Earnings released on 4 May 2023
EPS came in at -$0.78 falling short of the estimated -$0.70 by -11.43%, while revenue for the quarter reached $226.00K , beating expectations by +18.95%.
Earnings released on 23 Feb 2023
EPS came in at -$0.56 surpassing the estimated -$0.71 by +21.13%, while revenue for the quarter reached $253.00K , missing expectations by -6.79%.
Earnings released on 3 Nov 2022
EPS came in at -$0.76 falling short of the estimated -$0.71 by -7.04%, while revenue for the quarter reached $344.00K , missing expectations by -80.89%.
Earnings released on 4 Aug 2022
EPS came in at -$0.71 falling short of the estimated -$0.62 by -14.52%, while revenue for the quarter reached $365.00K , missing expectations by -82.48%.
Earnings released on 5 May 2022
EPS came in at -$0.61 surpassing the estimated -$0.63 by +3.17%, while revenue for the quarter reached $419.00K , beating expectations by +151.40%.
Earnings released on 24 Feb 2022
EPS came in at $0.36 surpassing the estimated -$0.60 by +160.00%, while revenue for the quarter reached $567.00K , missing expectations by -85.23%.
Earnings released on 10 Nov 2021
EPS came in at -$0.66 falling short of the estimated -$0.65 by -1.54%, while revenue for the quarter reached $666.00K , beating expectations by +1.56%.
Earnings released on 12 Aug 2021
EPS came in at -$2.10 falling short of the estimated -$0.48 by -337.50%, while revenue for the quarter reached $844.00K , meeting expectations.
Earnings released on 13 May 2021
EPS came in at -$0.47 surpassing the estimated -$0.48 by +2.08%, while revenue for the quarter reached $952.00K , missing expectations by -2.04%.
Earnings released on 25 Mar 2021
EPS came in at $0.70 surpassing the estimated $0.17 by +311.76%, while revenue for the quarter reached $82.65M .
Earnings released on 12 Nov 2020
EPS came in at -$0.51 falling short of the estimated -$0.35 by -45.71%.
RLAY Stock Performance
Access detailed RLAY performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.